Cabrespine Aurélie, Bay Jacques-Olivier, Verrelle Pierre, Morel Laurent
Service de thérapie cellulaire et d'hématologie clinique adultes, Pavillon Villemin-Pasteur, Hôtel-Dieu boulevard Léon-Malfreyt, 63058 Clermont-Ferrand.
Bull Cancer. 2007 Jul;94(7 Suppl):F29-34.
Interleukin-6 (IL-6) is secreted in great quantity in prostatic tumoral glandular tissue with a significant higher rate in hormono-refractory phase. Importance of IL-6 dependent mechanism in prostate cancer progression is well argued. IL-6 seems to be implicated in androgen receptor activation in lack of steroid ligand, apoptosis decrease and increase of invasive capacity and angiogenesis via three major signaling pathways: MAPK, STAT3 and PI3K-Akt. As AR is a key factor of prostate cancer progression, IL-6 implication in this activation underlines IL-6 importance in prostate cancer. IL-6 also induces neuroendocrine differentiation. This phenomenon received a detailed attention because it would take part in pathogenicity and progression of prostate cancer. Although complementary studies seem necessary, taking into account its strong implication in prostate cancer progression, IL-6 seems to be a new potential therapeutic target of prostate cancer.
白细胞介素-6（IL-6）在前列腺肿瘤腺组织中大量分泌，在激素难治期的分泌率显著更高。IL-6依赖性机制在前列腺癌进展中的重要性已得到充分论证。IL-6似乎通过三种主要信号通路：MAPK、STAT3和PI3K-Akt，在缺乏类固醇配体的情况下参与雄激素受体激活、减少细胞凋亡以及增加侵袭能力和血管生成。由于雄激素受体（AR）是前列腺癌进展的关键因素，IL-6参与这种激活凸显了其在前列腺癌中的重要性。IL-6还诱导神经内分泌分化。这一现象受到了详细关注，因为它可能参与前列腺癌的致病性和进展。尽管似乎需要补充研究，但考虑到IL-6在前列腺癌进展中的强烈参与，它似乎是前列腺癌一个新的潜在治疗靶点。
